Research recommendation(s) from an individual piece of guidance
- Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
- Date issued:
Research recommendations coming out of this guidance
- Research is needed to generate robust and relevant data on the effects of treating people with Alzheimer’s disease on both short-term and long-term outcomes, disease progression through relevant health states, and quality of life.
- Research is needed on the impact of treating Alzheimer’s disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).